1-3 of 3
Nathan Fowler, M.D.
Close
Sort by
Journal Articles

A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma.

Nathan Fowler, M.D., Peter McLaughlin, M.D., Fredrick B. Hagemeister, M.D., Larry Kwak, M.D., Ph.D., Michelle Fanale, M.D., Sattva Neelapu, M.D., Luis Fayad, M.D., Barbara Pro, M.D., Crystal Sergent, RN, MSN, Shana R. S. White, B.S., Felipe Samaniego, M.D.
Journal: Blood
Blood (2009) 114 (22): 1714.
https://doi.org/10.1182/blood.V114.22.1714.1714
Published: 2009
Journal Articles

Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response.

Jason R. Westin, MD, Michael A. Thompson, MD, PhD, Vince D. Cataldo, MD, Bela B. Toth, D.D.S., Perpetua Sanjorjo, Scott Bourgeois, M.D., Camilo Jimenez, M.D., William A. Murphy, M.D., Michelle Fanale, M.D., Luis Fayad, M.D., Nathan Fowler, M.D., Larry Kwak, MD, PHD, Peter McLaughlin, MD, Sattva Neelapu, MD, Barbara Pro, M.D., Alma Rodriguez, M.D., Jatin Shah, MD, Fredrick B. Hagemeister, MD
Journal: Blood
Blood (2009) 114 (22): 3922.
https://doi.org/10.1182/blood.V114.22.3922.3922
Published: 2009
Journal Articles

Bone Loss in Patients with Previously Untreated Lymphoma: The Effect of Periodontal Disease on the Use of Zoledronic Acid

Vince D. Cataldo, M.D., Michael A. Thompson, M.D., PhD, Bela B. Toth, D.D.S., Perpetua Sanjorjo, B. Nebiyou Bekele, PhD, Camilo Jimenez, M.D., William A. Murphy, M.D., Auris O. Huen, Pharm.D., Rebecca B. Arbuckle, Pharm.D., Michelle A. Fanale, M.D., Luis E. Fayad, M.D., Nathan Fowler, M.D., Larry W. Kwak, M.D., Peter W. McLaughlin, M.D., Sattva S. Neelapu, M.D., Barbara Pro, M.D., Alma Rodriguez, M.D., Jatin Shah, M.D., Fredrick B. Hagemeister, M.D.
Journal: Blood
Blood (2008) 112 (11): 5297.
https://doi.org/10.1182/blood.V112.11.5297.5297
Published: 2008